drugset / Trial / NCT00401544
Darbepoetin Alfa With or Without Intravenous (IV) Iron
RandomizedFactorialQuadruple-blindTreatment
Summary
To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients with non-myeloid malignancies who were receiving multicycle chemotherapy.
Timeline
- Start
- 2006-12
- Primary completion
- 2007-12
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 300 ug | Subcutaneous |
| Subject | Darbepoetin alfa | Protein / enzyme biologic | 500 ug | Subcutaneous |
| Subject | Iron dextran | Unknown | 400 mg | Intravenous |